Partners4Access Expands Top Leadership with New Appointment
Akshay brings a wealth of market access experience built over a decade from previous roles with Huron as Senior Director – Orphan Drugs, Cell & Gene Therapy commercialization and at ZS Associates as European Market Access and Pricing Leader.
Speaking about the appointment, Sophie Schmitz, Managing Partner, P4A said, " I am delighted to have Akshay as part of our team. He is an experienced leader having driven major market access projects in orphan drugs, cell and gene therapy focusing on value communications, evidence mitigation, pricing and go-to-market access strategy."
She added "P4A has a strong reputation for recognizing talent who make a real difference in supporting clients' challenges in particular within the specialist areas of rare disease and cell and gene therapy. Having Akshay as one of our top leaders will ensure P4A's continued success."
"I am very excited to join the growing P4A team who are 100% focused on working with orphan drug clients to develop access and commercialization solutions. I strongly believe innovative thinking and development of bespoke, actionable solutions that speaks to each client's unique situation- is imperative for driving orphan drug commercialization success. P4A's engagement model grounded in close partnership with clients will facilitate this solution-focused thinking vs. the traditional consulting model that is more short-term."
Akshay Kumar will be based in the company's London office.
Partners4Access are experts in orphan drug, cell and gene therapy access, partnering with the biotechnology industry to support launches worldwide.
Our services focus on five key areas: orphan drugs pricing and market access strategy; bespoke access roadmap; rare disease foresights; evidence mitigation solutions; access team excellence.
As one of the only consultancies with comprehensive experience in cell and gene therapies, P4A are excellently placed to help clients successfully achieve access.
Through various media initiatives, P4A are able to inform and shape the conversation around orphan drugs.
The team at P4A believe in striking an equilibrium in the rare disease world. That means helping drive access to the most appropriate treatments for patients and physicians, a fair return on investment for manufacturers at an affordable proposition for payers.
For more information, please visit P4A's website: www.partners4access.com or email at firstname.lastname@example.org.